Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Justine Badee | Drug Metabolism | Best Researcher Award

Dr. Justine Badee | Drug Metabolism | Best Researcher Award

Scientist from Novartis, Switzerland

Dr. Justine Badée is a distinguished pharmacokinetics researcher with over eight years of experience in the pharmaceutical industry, primarily focusing on physiologically-based pharmacokinetic (PBPK) modeling. Currently serving as a Principal Scientist II at Novartis in Basel, Switzerland, she leads modeling efforts to support drug development from First-in-Human studies to regulatory submissions. Dr. Badée holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Manchester and has a strong foundation as a pharmacist and researcher. Her work encompasses a wide range of applications including drug-drug interactions, pediatric dosing, lactation modeling, and biopharmaceutic assessments. In addition to her scientific contributions, she has mentored Ph.D. students, driven external collaborations with international organizations such as Simcyp and the IQ Consortium, and delivered presentations at leading global conferences. Her multi-disciplinary approach and applied modeling expertise have led to significant advancements in PBPK methodologies and their regulatory application. Dr. Badée has authored and co-authored numerous scientific publications and contributed actively to the development of industry best practices in pharmacokinetics. She is recognized not only for her technical excellence but also for her leadership, mentoring, and collaborative spirit, making her a key contributor to the field of clinical pharmacology and drug metabolism.

Professional Profile

Education

Justine Badée possesses a comprehensive and rigorous academic background in pharmacokinetics and pharmaceutical sciences. She completed her Ph.D. in Pharmacokinetics and Drug Metabolism at the Centre for Applied Pharmacokinetic Research (CAPkR), University of Manchester, UK, where she focused on hepatic uptake clearance and its in vitro to in vivo translation. Her research was supported by joint funding from AstraZeneca and the UK Biotechnology and Biological Sciences Research Council. Prior to her doctoral studies, she earned a Master’s degree in Pharmacokinetics from the Faculty of Pharmacy at University René Descartes V in Paris, France. Additionally, she holds a pharmacy degree from the same institution, completing her training as a licensed pharmacist. Her academic foundation was further strengthened by a scientific high school diploma with a physics major from Saint-Erembert High School in France. Dr. Badée’s academic journey has not only equipped her with a solid theoretical and experimental knowledge base but also cultivated a robust understanding of pharmacological principles and translational research. Her diverse educational pathway—spanning pharmaceutical sciences, clinical pharmacokinetics, and drug metabolism—has played a critical role in her ability to engage in complex modeling tasks and collaborative international research efforts in drug development.

Professional Experience

Dr. Justine Badée’s professional experience reflects a dynamic and upward trajectory in the pharmaceutical and academic sectors. Since 2019, she has been a Clinical PBPK Modeler and Principal Scientist II at Novartis in Basel, where she applies PBPK modeling to a range of clinical drug development scenarios, including DDI predictions, population-specific dosing, and regulatory submissions. She also completed a three-month managerial rotation as a Project Team Manager in oncology, supporting protocol design and pharmacokinetic analysis. Her prior postdoctoral work was jointly conducted at the Center for Pharmacometrics and Systems Pharmacology, University of Florida, and at Hoffmann-La Roche, where she advanced pediatric dose selection by investigating UGT enzyme ontogeny. As a Ph.D. student at the University of Manchester, she led projects on hepatic uptake clearance and nonlinear mixed-effects modeling. Earlier in her career, she held internships at Novartis and INSERM and served as an extern pharmacist at Beaujon Hospital in Paris. Across roles, she has integrated bench research, computational modeling, and clinical applications, resulting in a comprehensive skill set. Her trajectory from laboratory-based research to high-level modeling in an industrial setting exemplifies her adaptability, technical expertise, and commitment to translating pharmacokinetic theory into practice.

Research Interests

Dr. Badée’s research interests lie at the intersection of pharmacokinetics, drug metabolism, and translational modeling. A key focus of her work is the development and application of physiologically-based pharmacokinetic (PBPK) models to optimize drug dosing, predict drug-drug interactions, and inform regulatory decisions. She is particularly interested in special populations—pediatrics, lactating women, and patients with hepatic or renal impairment—where traditional pharmacokinetic approaches often fall short. Her research extends into enzyme ontogeny, especially hepatic UGT isoforms, and how their developmental profiles affect drug metabolism across life stages. Dr. Badée is also engaged in refining in vitro methodologies to better predict in vivo drug behavior, with a focus on improving the reliability of automated glucuronidation assays. Her interest in translational research is evident through her active involvement in industry consortia and collaborative initiatives aimed at improving PBPK workflows and regulatory confidence. Furthermore, she explores innovative model-based approaches to address complex drug development challenges, such as enzyme induction and transporter-mediated drug disposition. Through these pursuits, she contributes to bridging gaps between laboratory findings, clinical implementation, and regulatory science, demonstrating a keen interest in both theoretical development and real-world application of pharmacokinetic modeling.

Research Skills

Dr. Justine Badée possesses a robust portfolio of research skills spanning pharmacokinetic modeling, laboratory techniques, and collaborative project execution. Her core technical competencies include physiologically-based pharmacokinetic (PBPK) modeling using tools such as Simcyp, GastroPlus, and PK-Sim, as well as nonlinear mixed-effect (NLME) modeling with NONMEM. She is adept at both population pharmacokinetics and PK/PD modeling, utilizing software such as WinNonlin/Phoenix, GraphPad Prism, and R. In laboratory settings, she has conducted molecular biology experiments, bioanalytical quantification using LC-MS/MS, protein assays, and hepatocyte isolation, among others. Her experience includes designing and optimizing in vitro uptake and glucuronidation assays to model hepatic metabolism accurately. Dr. Badée’s skills extend beyond the bench and computational tasks—she is also a skilled scientific communicator and collaborator. She has mentored Ph.D. students, led cross-functional teams, and actively participated in international scientific workshops and training programs. Her ability to integrate laboratory findings into advanced modeling platforms reflects her interdisciplinary expertise. Collectively, these skills position her as a valuable contributor to both the academic and industry research ecosystems, ensuring she can translate complex scientific questions into actionable insights for drug development and regulatory strategy.

Awards and Honors

Throughout her career, Dr. Justine Badée has received multiple prestigious awards and recognitions for her scientific excellence and research impact. These include the IQ Recognition Award (2021), the American College of Clinical Pharmacology (ACCP) Wayne A. Colburn Memorial Award (2018), and the ACCP Student Award. Her poster presentations have consistently garnered top honors, winning first-place awards at the Drug Metabolism Discussion Group (DMDG) and Group of Metabolism and Pharmacokinetics (GMP) meetings in 2013 and 2014. In 2023, she received a poster award at the Marbach Drug-Drug Interaction Workshop, further underscoring her contributions to advancing PBPK modeling. In addition to these accolades, she received a certificate of outstanding reviewer for the European Journal of Pharmaceutical Sciences in 2018, recognizing her critical evaluation and contribution to scientific literature. These awards reflect both the scientific rigor and practical relevance of her research. Her consistent recognition by professional bodies and conference committees highlights her leadership in modeling-based drug development and her commitment to excellence in pharmacological science. Dr. Badée’s accolades not only mark her individual achievements but also affirm her role in shaping current and future best practices in pharmacokinetic research.

Conclusion

In conclusion, Dr. Justine Badée represents a rare combination of scientific depth, practical impact, and collaborative leadership in the field of pharmacokinetics. Her contributions span the full spectrum of drug development—from mechanistic in vitro studies to sophisticated PBPK modeling and regulatory submissions. She has successfully bridged academia and industry, delivering actionable solutions to complex pharmacokinetic challenges. Her numerous peer-reviewed publications, awards, and leadership in international collaborations reflect a researcher deeply engaged in advancing the field and mentoring the next generation. With her ability to innovate, communicate, and translate science into therapeutic outcomes, Dr. Badée has established herself as a leading figure in modeling and simulation. Her work not only informs clinical and regulatory decisions but also contributes to safer and more effective drug use in vulnerable populations. As she continues to build on this strong foundation, her career promises further innovations in model-informed drug development. Dr. Badée is an ideal candidate for recognition through the Best Researcher Award, and her work exemplifies the highest standards of scientific inquiry and professional dedication.

Publications Top Notes

  • Predicting Drug Transfer into Human Milk with the Simcyp Simulator: A contribution from the ConcePTION Project
    Macente J, Nauwelaerts N, Badée J, Huang MC, Hernandes Bonan R, Van Neste M, Smits A, Allegaert K, Severino Martins F, Annaert P.
    2025

  • Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
    Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, Badée J, Bolleddula J, Boulu L, Fu Q, Kotsuma M, Leblanc AF, Lewis G, Liang G, Parrott N, Pilla Reddy V, Prakash C, Shah K, Umehara K, Mupkherjee D, Rehmel J, Hariparsad N.
    2025

  • Generic workflow to predict medicine concentrations in human milk using physiologically-based pharmacokinetic (PBPK) modelling – A contribution from the concePTION project
    Nauwelaerts N, Macente J, Hernandes Bonan R, Huang MC, Van Neste M, Bibi D, Badée J, Martins FS, Smiths A, Allegaert K, Bouillon T, Annaert P.
    2023

  • Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective
    Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emani Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N.
    2021

  • Characterization of Hepatic UDP-Glucuronosyl Transferase Enzymes Abundance – Activity Correlations and Population Variability using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes
    Takahashi RH, Forrest W, Smith AD, Badée J, Qiu N, Schmidt S, Collier CA, Parrott N, Fowler S.
    2021

  • Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species
    van Groen BD, Nicolaï J, Kuik AC, van Cruchten S, van Peer E, Schmidt S, de Wildt SN, Allegaert K, de Schaepdrijver L, Annaert P, Badée J.
    2021

  • Paediatric pharmacokinetics and dose predictions: a report of a satellite meeting to the 10th Juvenile Toxicity Symposium
    van Groen BD, Pilla Reddy V, Badée J, Olivares-Morales A, Johnson TN, Nicolaï J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L.
    2021

  • Co-expression of human hepatic uridine diphosphate glucuronosyltransferase (UGT) proteins: Implications for ontogenetic mechanisms and isoform co-regulation
    Liu Y, Badée J, Takahashi RH, Schmidt S, Parrott N, Fowler S, Mackenzie PI, Coughtrie MWH, Collier AC.
    2020

  • Use of Phenotypically Poor Metaboliser Individual Donor Human Liver Microsomes to Identify Selective Substrates of UGT2B10
    Milani N, Qiu N, Molitor B, Badée J, Cruciani G, Fowler S.
    2020

  • Characterization of the Ontogeny of Hepatic UDP-Glucuronosyl Transferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes
    Badée J, Qiu N, Collier CA, Takahashi RH, Forrest W, Parrott N, Schmidt S, Fowler S.
    2019

JAWAHAR NATARAJAN | Nano Drug Delivery | Excellence in Research

Dr. JAWAHAR NATARAJAN | Nano Drug Delivery | Excellence in Research

Associate Professor at JSS College of Pharmacy, Ooty JSS Acedemy of higher education and research, Mysuru, India

Dr. Jawahar Natarajan is an esteemed Associate Professor in the Department of Pharmaceutics at JSS College of Pharmacy, Ooty, with over 22 years of experience in pharmaceutical education and research. He earned his Ph.D. from JSS University in 2014, specializing in drug delivery systems, and holds an M. Pharm in Pharmaceutics. Dr. Natarajan has guided several Ph.D. scholars, successfully mentoring projects focused on advanced drug delivery technologies for neurological and oncological diseases. His extensive research contributions include numerous M. Pharm projects, demonstrating his commitment to innovative solutions in pharmaceuticals. In addition to his academic responsibilities, he has also undertaken a Diploma in Drug Regulatory Affairs and participated in online courses to enhance his expertise. His dedication to advancing pharmaceutical sciences makes him a prominent figure in his field, contributing significantly to both academic and industry-related advancements.

Profile

Education

Dr. Jawahar Natarajan completed his Ph.D. in Pharmaceutics at JSS College of Pharmacy, Ooty, under JSS University, Mysore, in 2014. He also holds a Master of Pharmacy (M.Pharm) degree in Pharmaceutics from K.M. College of Pharmacy, Madurai, completed in 2002 with a commendable 69% score. His academic journey began with a Bachelor of Pharmacy (B.Pharm) from A.K. College of Pharmacy, Krishnan Kovil, in 1999, where he graduated with 61%. In addition to his formal degrees, Dr. Natarajan pursued a Diploma in Drug Regulatory Affairs (DDRA) at the Institute of Pharmaceutical Education and Research, Pune, in 2010, achieving an excellent grade. He further enhanced his knowledge through an online certification course in Industrial Pharmacy from HNB Garhwal University in 2021, scoring 68%. Dr. Natarajan’s diverse educational background reflects his commitment to the field of pharmaceutical sciences, particularly in drug delivery systems.

Professional Experience

Dr. Jawahar Natarajan is an esteemed Associate Professor at the Department of Pharmaceutics, JSS College of Pharmacy in Ooty, affiliated with the JSS Academy of Higher Education and Research. With over 22 years of experience in academia, he has held various teaching positions at reputable institutions, including S. Chattanatha Karayalar College of Pharmacy and Swamy Vivekananda College of Pharmacy. Since joining JSS College of Pharmacy in 2007, Dr. Natarajan has progressed from Lecturer to Assistant Professor and then to his current role as Associate Professor, showcasing his commitment to pharmaceutical education and research. He has guided numerous Ph.D. scholars and M. Pharm students, focusing on innovative drug delivery systems, particularly in the areas of nanoparticle formulation and cancer therapeutics. Dr. Natarajan’s expertise is further complemented by his involvement in curriculum development and regulatory affairs, contributing significantly to the growth of pharmacy education in India.

Research Interest

Dr. Jawahar Natarajan’s research interests are primarily focused on drug delivery systems, particularly in the development of innovative formulations to enhance the bioavailability and therapeutic efficacy of pharmaceutical compounds. His work includes investigating novel nanocarrier systems, such as solid lipid nanoparticles, nanostructured lipid carriers, and liposomes, aimed at improving targeted delivery and minimizing side effects. Dr. Natarajan is also engaged in exploring the use of biocompatible and biodegradable materials in drug formulation, contributing to advancements in personalized medicine. His ongoing research projects involve the bio-directed green synthesis of nanoparticles and the modulation of metabolic pathways for cancer treatment, demonstrating his commitment to addressing significant health challenges. Additionally, Dr. Natarajan actively mentors Ph.D. scholars and oversees various M. Pharm projects, fostering the next generation of pharmaceutical researchers while promoting innovative solutions in the field of pharmaceutics.

Research Skills

Dr. Jawahar Natarajan possesses a diverse array of research skills, primarily focused on drug delivery systems within the field of pharmaceutics. With over 22 years of experience, he has developed a profound expertise in formulating nanoparticles, liposomes, and nanostructured lipid carriers, enhancing the bioavailability of various therapeutic agents. His proficiency extends to guiding Ph.D. scholars and M. Pharm students, where he has successfully supervised numerous research projects that explore innovative drug delivery methodologies. Dr. Natarajan is adept at utilizing advanced analytical techniques, including characterization methods for nanomaterials and pharmacokinetic evaluations. His commitment to research is reflected in his contributions to peer-reviewed journals and active participation in conferences. Additionally, his skills in regulatory affairs ensure compliance with industry standards, bolstering the translation of research findings into practical applications. Overall, Dr. Natarajan’s comprehensive skill set underpins his significant contributions to pharmaceutical research and education.

Award and Recognition

Dr. Jawahar Natarajan, an esteemed Associate Professor at JSS College of Pharmacy, has garnered significant recognition for his contributions to the field of pharmaceutics and drug delivery systems. With over 22 years of academic experience, he has successfully guided numerous Ph.D. and M. Pharm. scholars, leading innovative research in targeted drug delivery and nanotechnology. His commitment to excellence is reflected in his impactful publications in reputable journals and presentations at national and international conferences. Dr. Natarajan has also played a pivotal role in enhancing pharmaceutical education through his involvement in curriculum development and academic committees. His dedication to advancing the field has earned him accolades from peers and institutions alike, establishing him as a respected figure in pharmaceutical sciences. Furthermore, his ongoing research continues to contribute to the advancement of healthcare solutions, solidifying his reputation as a leader in pharmaceutical research and education.

Conclusion

Jawahar N. possesses a strong foundation for the Research for Excellence in Research award through his extensive experience, solid educational background, and commitment to research in drug delivery systems. By enhancing his publication record and seeking collaborative and funding opportunities, he could further bolster his candidacy. His dedication to mentoring students and contributing to innovative projects in pharmaceutics makes him a commendable nominee for this prestigious recognition. Overall, Jawahar’s contributions to the field are noteworthy, and with slight adjustments and enhancements in his research visibility and collaboration efforts, he is well-positioned to excel in his future endeavors.

Publication Top Notes
  1. Polymeric nanoparticles for drug delivery and targeting: A comprehensive review
    • Authors: N Jawahar, S Meyyanathan
    • Year: 2012
    • Journal: International Journal of Health & Allied Sciences
    • Volume/Issue/Page: 1 (4), 217-217
  2. Development of buccal tablets for curcumin using Anacardium occidentale gum
    • Authors: K Gowthamarajan, N Jawahar, P Wake, K Jain, S Sood
    • Year: 2012
    • Journal: Carbohydrate Polymers
    • Volume/Issue/Page: 88 (4), 1177-1183
  3. Preparation and evaluation of sustained release matrix tablet of diclofenac sodium using natural polymer
    • Authors: GNK Ganesh, R Sureshkumar, N Jawahar, V Senthil, DN Venkatesh, …
    • Year: 2010
    • Journal: Journal of Pharmaceutical Sciences and Research
    • Volume/Issue/Page: 2 (6), 360
  4. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers
    • Authors: N Jawahar, PK Hingarh, R Arun, J Selvaraj, A Anbarasan, …
    • Year: 2018
    • Journal: International Journal of Biological Macromolecules
    • Volume/Issue/Page: 110, 269-275
  5. Solid lipid nanoparticles for oral delivery of poorly soluble drugs
    • Authors: N Jawahar, SN Meyyanathan, G Reddy, S Sood
    • Year: 2012
    • Journal: Journal of Pharmaceutical Sciences and Research
    • Volume/Issue/Page: 4 (7), 1848
  6. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability
    • Authors: S Sood, N Jawahar, K Jain, K Gowthamarajan, S Nainar Meyyanathan
    • Year: 2013
    • Journal: Current Nanoscience
    • Volume/Issue/Page: 9 (1), 26-34
  7. Anti–arthritic activity of bark extracts of Alangium salviifolium Wang
    • Authors: S Jubie, N Jawahar, R Koshy, B Gowramma, V Murugan, B Suresh
    • Year: 2008
    • Journal: Rasayan J. Chem
    • Volume/Issue/Page: 1 (3), 433-436
  8. Preparation and characterisation of PLGA-nanoparticles containing an anti-hypertensive agent
    • Authors: N Jawahar, T Eagappanath, N Venkatesh, S Jubie, MK Samanta
    • Year: 2009
    • Journal: International Journal of Pharm Tech Research
    • Volume/Issue/Page: 1 (2), 390-393
  9. Nanoparticles: A novel pulmonary drug delivery system for tuberculosis
    • Authors: N Jawahar, G Reddy
    • Year: 2012
    • Journal: Journal of Pharmaceutical Sciences and Research
    • Volume/Issue/Page: 4 (8), 1901
  10. Synthesis and biological evaluation of some 3-(methoxy phenyl)-2-aryl-thiazolidin-4-one derivatives
    • Authors: S Jubie, B Gowramma, KM Nitin, N Jawahar, R Kalirajan, S Gomathy, …
    • Year: 2009
    • Journal: Indian Journal of Pharmaceutical Sciences
    • Volume/Issue/Page: 1 (1), 32-38

 

 

 

 

Priyanka Varne | Drug Delivery | Best Researcher Award

Mrs. Priyanka Varne | Drug Delivery | Best Researcher Award

Nurse Practitioner at UNC Blue Ridge, United States.

Priyanka Bhushan Varne is an accomplished Assistant Professor in the Department of Pharmaceutical Chemistry at Bharati Vidyapeeth College of Pharmacy, Kolhapur. With a total of 10 years of experience in academia and industry, she has a strong background in research and teaching. Currently pursuing her Ph.D. at Shivaji University, she has published multiple papers in prestigious international journals, focusing on innovative drug delivery systems and enhancing bioavailability through techniques like liquisolid compacts. Her expertise spans various areas, including formulation development and analytical method validation. In addition to her research contributions, Priyanka possesses strong skills in communication, leadership, and critical thinking, which enhance her effectiveness as an educator. She has also filed a patent, showcasing her commitment to innovation in pharmaceutical sciences. With a dedication to academic integrity and continuous improvement, Priyanka is well-positioned to make significant contributions to her field.

Profile:

Education

Priyanka Bhushan Varne is currently pursuing her Ph.D. at Shivaji University, Kolhapur, where she focuses on advanced topics in pharmaceutical chemistry. She holds a Master’s degree in Pharmacy (M. Pharm) from the same institution, which provided her with a solid foundation in drug formulation and development. Her academic journey began with a Bachelor’s degree in Pharmacy (B. Pharm), also from Shivaji University, where she developed a keen interest in pharmaceutical sciences. Throughout her academic career, Priyanka has demonstrated a commitment to excellence in her studies, which is reflected in her strong research background and her ability to publish in reputed international journals. Her ongoing education, combined with her teaching experience at Bharati Vidyapeeth College of Pharmacy, Kolhapur, further enhances her expertise and positions her as a knowledgeable academic in the field of pharmaceutical chemistry.

Professional Experiences 

Priyanka Bhushan Varne is an accomplished academician with a decade of professional experience in the field of pharmaceutical chemistry. She has served as an Assistant Professor at Bharati Vidyapeeth College of Pharmacy in Kolhapur for three years, where she has contributed to both teaching and research. Prior to this role, she spent three years as a research scholar at the same institution, honing her skills in research methodologies and publication processes. Her career also includes two years of teaching experience at MSS’s College of Pharmacy in Medha, Satara. Additionally, Priyanka has two years of industrial experience at Micro Labs Ltd in Verna, Goa, where she applied her theoretical knowledge to real-world pharmaceutical challenges. Throughout her career, she has focused on innovative drug delivery systems, enhancing bioavailability, and developing analytical methods, resulting in multiple publications in esteemed international journals. Her blend of academic and industry experience makes her a valuable asset to the field.

Research Interests

Priyanka Bhushan Varne’s research interests primarily lie in the field of pharmaceutical chemistry, focusing on the design and development of innovative drug delivery systems. She is particularly interested in enhancing the bioavailability and dissolution properties of poorly soluble drugs through advanced techniques such as liquisolid compacts and solid dispersion methods. Her work encompasses the formulation of fast-dissolving tablets and films, which aim to improve patient compliance and therapeutic efficacy. Additionally, Priyanka explores cosolvency in analytical method development, striving to optimize the analytical techniques used in pharmaceutical formulations. She actively investigates the pharmacological effects of various compounds, contributing to the understanding of their mechanisms in treating conditions such as hypertension and cancer. With a strong foundation in both research and teaching, Priyanka aims to bridge the gap between theoretical knowledge and practical applications, making significant strides in the advancement of pharmaceutical sciences and patient care.

Research skills 

Priyanka Bhushan Varne possesses a robust set of research skills that significantly contribute to her effectiveness as a researcher in pharmaceutical chemistry. With a strong foundation in publication writing, she has successfully authored multiple papers in reputed international journals, demonstrating her ability to communicate complex scientific concepts clearly and effectively. Her skills in analytical techniques enable her to design and conduct experiments that explore innovative drug delivery systems, such as liquisolid compacts. Additionally, Priyanka exhibits exceptional time management and critical thinking abilities, allowing her to balance teaching responsibilities while pursuing her Ph.D. and engaging in research. Her leadership skills foster collaboration with colleagues and students, enhancing the overall research environment. Furthermore, her commitment to academic integrity and ethical research practices underscores her professionalism and reliability in scientific inquiry. Overall, her diverse research skills make her a valuable asset to the academic community and a promising candidate for advancing pharmaceutical sciences.

Award and Recognition 

Priyanka Bhushan Varne has garnered significant recognition for her contributions to the field of pharmaceutical chemistry. Her dedication to research is evidenced by her multiple publications in esteemed international journals, achieving recognition in Q1, Q2, and Q3 quartiles. She has also been awarded a patent, reflecting her innovative approach to drug delivery systems. Priyanka’s commitment to academic excellence extends beyond her research, as she actively engages in teaching and mentoring students at Bharati Vidyapeeth College of Pharmacy. Her leadership skills and effective communication have earned her accolades within the academic community, fostering collaboration and knowledge sharing. Additionally, her ongoing pursuit of a Ph.D. from Shivaji University further underscores her commitment to advancing her expertise. These achievements collectively highlight her potential for further contributions and innovations in pharmaceutical research, making her a respected figure in her field.

Conclusion

Priyanka Bhushan Varne is a dedicated and experienced researcher deserving of the Best Researcher Award. Her extensive publication record, commitment to innovative research, and strong academic credentials highlight her contributions to the field of pharmaceutical chemistry. By addressing the identified areas for improvement, she can further enhance her impact and recognition in the academic community. Awarding her this recognition would not only honor her achievements but also inspire continued excellence and innovation in her research endeavors.

Publication Top Notes
  1. Design and development of Fujicalin-based axitinib liquisolid compacts for improved dissolution and bioavailability to treat renal cell carcinoma
    • Authors: Yadav, P.S., Hajare, A.A., Patil, K.S.
    • Year: 2024
    • Journal: European Journal of Pharmaceutics and Biopharmaceutics
    • Volume/Issue/Page: 204, 114506
  2. Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates
    • Authors: Yadav, P.S., Hajare, A.A., Patil, K.S.
    • Year: 2024
    • Journal: Journal of Dispersion Science and Technology
    • Volume/Issue/Page: 45(6), pp. 1227–1240
    • Citations: 1
  3. Development and Validation of UV Spectrophotometric Method for Doxazosin Mesylate in Bulk and Tablets
    • Authors: Yadav, P.S., Hajare, A.A., Patil, K.S.
    • Year: 2022
    • Journal: Research Journal of Pharmacy and Technology
    • Volume/Issue/Page: 15(6), pp. 2765–2680
    • Citations: 4

 

 

Moein Masjedi | Pharmacology | Best Researcher Award

Moein Masjedi | Pharmacology | Best Researcher Award

Moein Masjedi, DarooSazan Sorena Exir Pharmaceutical Company, Iran.

Moein Masjedi is a dedicated researcher in the field of pharmacology, recognized for his innovative contributions to drug development and therapeutic strategies. With a strong academic background and a commitment to advancing scientific knowledge, he has published numerous influential papers that address critical challenges in the field. Awarded the Best Researcher Award for his outstanding research impact, Moein continues to inspire peers and students through his passion for improving health outcomes and enhancing patient care.

Profile:

Education

Moein Masjedi earned his Doctor of Pharmacy degree from Shiraz University of Medical Sciences in Shiraz, Fars, Iran, where he completed his thesis on the drug utilization evaluation of captopril in two coronary care units at Namazi Hospital, achieving a GPA of 15.64 out of 20. He then pursued a Ph.D. in Pharmaceutics at the same institution, focusing on the nose-to-brain delivery of Sumatriptan using chitosan nanoparticles and nanostructured lipid carriers (NLCs), and graduated with a GPA of 17.83 out of 20.

 

Skills 

Moein Masjedi possesses a diverse skill set that enhances his effectiveness as a researcher and collaborator. He excels in strong and collaborative communication, fostering teamwork and idea exchange. His creativity in problem-solving and critical thinking enables him to tackle complex challenges in pharmacology. Demonstrating leadership qualities, he effectively manages projects while prioritizing time management to meet deadlines. Additionally, he is skilled in structural scientific writing and proofreading, ensuring clarity and precision in his research publications. Beyond academia, Moein has a passion for art interpretation and enjoys swimming and yoga, which contribute to his overall well-being and work-life balance.

Areas of Interest:

Moein Masjedi’s research interests focus on innovative drug delivery systems and formulation design. He is particularly passionate about nanoparticulate drug delivery and the optimization of formulations for pulmonary, ocular, topical, and transdermal applications. His work includes designing novel drug delivery systems targeting specific sites such as the pulmonary system, colon, brain, and hair follicles. He explores the use of nanovesicles, lipid, and polymeric nanoparticles for both therapeutic and cosmetic applications. Additionally, Moein is interested in D-optimal optimization of aesthetic formulations and the development of stimuli-responsive or smart polymers for drug delivery. He employs Design of Experiments (DoE) methodologies to optimize formulations and is also engaged in the innovative 3D printing of pharmaceutical dosage forms, aiming to advance the field of pharmaceutics.

Publication Top Notes

  1. Masjedi, M., Izadi, Y., Montahaei, T., Mohammadi, R., Helforoush, M. A., & Rohani Rad, K. (2024). An illustrated review on herbal medicine used for the treatment of female infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology, 0(0).
  2. Dahri, M., Beheshtizadeh, N., Seyedpour, N., Nakhostin-Ansari, A., Aghajani, F., Seyedpour, S., Masjedi, M., Farjadian, F., Maleki, R., & Adibkia, K. (2023). Biomaterial-based delivery platforms for transdermal immunotherapy. Biomedicine & Pharmacotherapy, 165, 115048.
  3. Rezaie, F., Farshbaf, M., Dahri, M., Masjedi, M., Maleki, R., Amini, F., Wirth, J., Moharamzadeh, K., Weber, F. E., & Tayebi, L. (2023). 3D printing of dental prostheses: Current and emerging applications. Journal of Composites Science, 7(2), 80.
  4. Masjedi, M., Montahaei, T., Sharafi, Z., & Jalali, A. (2022). Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy. Journal of Drug Delivery Science and Technology, 103184.
  5. Masjedi, M., & Solhjoo, A. (2022). Does trigonelline help skin tone? Molecular docking studies of trigonelline on the human tyrosinase, formulation, optimization and characterization of an emulgel containing Trigonella foenum‐graecum L. fenugreek standardized hydroalcoholic extract. Journal of Cosmetic Dermatology.
  6. Masjedi, M., & Namazi, S. (2020). Drug utilization evaluation (DUE) of captopril in two coronary care units (CCU) of Namazi Hospital, Shiraz, Iran.
  7. Masjedi, M., & Montahaei, T. (2020). An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications. Journal of Drug Delivery Science and Technology, 102234.
  8. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi-Samani, S. (2020). Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: Preparation, in vitro characterization, and (neuro-) pharmacokinetic evaluations. Journal of Drug Delivery Science and Technology, 102179.
  9. Ziaei, A., Davoodian, P., Dadvand, H., Safa, O., Hassanipour, S., Omidi, M., Masjedi, M., Mahmoudikia, F., Rafiee, B., & Fathalipour, M. (2020). Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 1-3.
  10. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi‐Samani, S. (2020). Nose‐to‐brain delivery of sumatriptan‐loaded nanostructured lipid carriers: Preparation, optimization, characterization, and pharmacokinetic evaluation. Journal of Pharmacy and Pharmacology, 72(10), 1341-1351.

Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Dr. Kifayat Ullah Shah | Pharmaceutics | Best Researcher Award

Associate Professor at Quaid-i-Azam University, Pakistan

Dr. Kifayat Ullah Shah is an accomplished academic and researcher in the field of pharmaceutical sciences, currently serving as an Associate Professor at Quaid-e-Azam University in Islamabad since September 2014. He previously held positions as an Assistant Professor at Hamdard University and a Teaching Assistant at Gomal University. Dr. Shah earned his Ph.D. in Pharmaceutics from Gomal University, where he also completed his Bachelor of Pharmacy. His research interests include the formulation and development of pharmaceuticals, controlled drug delivery, and nanotechnology applications in drug delivery. He has authored several publications with significant impact, reflecting his contributions to the field, and has supervised over 35 MPhil and five PhD students. Dr. Shah has received grants for various research projects, showcasing his commitment to advancing pharmaceutical sciences. Additionally, he is actively involved in academic administration and quality assurance within higher education.

Education

Dr. Kifayat Ullah Shah holds an impressive educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (Ph.D.) in Pharmaceutics from Gomal University, Dera Ismāīl Khān, Khyber Pakhtunkhwa, Pakistan, between 2008 and 2014. Prior to that, he obtained a Bachelor of Pharmacy (B.Pharmacy) degree from the same institution, Gomal University, from 2002 to 2006. His early education includes a Pre-Medical F.Sc. from Govt. P.G. College Bannu in 2000-2001 and Matriculation in Science from Govt. High School-02 Bannu in 1998-1999. This strong academic foundation has equipped Dr. Shah with the knowledge and skills necessary to excel in both research and teaching within the field of pharmaceutical sciences.

Professional Experience

Dr. Kifayat Ullah Shah has extensive professional experience in academia and the pharmaceutical industry. He has served as an Associate Professor at Quaid-e-Azam University, Islamabad, since September 2014, where he has contributed to teaching and research in pharmaceutical sciences. Prior to this role, Dr. Shah was an Assistant Professor at Hamdard University from January to August 2014 and worked as a Teaching Assistant at Gomal University for a brief period in late 2011. His early career included experience as a Production Pharmacist at Glitz Pharmaceuticals in Islamabad, where he gained practical insights into pharmaceutical production and formulation. Dr. Shah’s diverse professional background, coupled with his research focus on drug delivery systems and nanotechnology, has positioned him as a prominent figure in his field.

Research Interest

Dr. Kifayat Ullah Shah’s research interests are centered around the formulation and development of pharmaceutical products, with a particular focus on controlled drug delivery systems. His expertise encompasses a variety of advanced techniques, including microencapsulation, nanotechnology, and thermal analysis, which he applies to improve the efficacy and safety of drug formulations. Dr. Shah has conducted significant research on targeted drug delivery mechanisms, exploring innovative methods to enhance therapeutic outcomes for various medical conditions. His work also includes the design, preparation, and evaluation of controlled release polymeric formulations, aiming to investigate drug release patterns and mechanisms. Through his research, Dr. Shah seeks to contribute to the advancement of pharmaceutical sciences and improve patient care through effective drug delivery systems.

Research Skills

Dr. Kifayat Ullah Shah possesses a robust skill set in pharmaceutical research, particularly in the formulation and development of drug delivery systems. His expertise includes advanced techniques such as microencapsulation, controlled drug delivery, and targeted drug delivery, which are essential for optimizing the therapeutic effects of pharmaceuticals. Dr. Shah is proficient in utilizing various analytical instruments, including UV/Visible spectrophotometry, differential scanning calorimetry (DSC), and thermal analysis, to evaluate and characterize pharmaceutical formulations. His research skills also extend to pre-formulation studies and the application of nanotechnology in drug delivery, enabling him to design innovative solutions for complex pharmaceutical challenges. Through his comprehensive knowledge and practical experience, Dr. Shah effectively contributes to the advancement of pharmaceutical sciences and the development of new therapeutic strategies.

Award and Recognition

Dr. Kifayat Ullah Shah has garnered several awards and recognitions throughout his career, highlighting his significant contributions to the field of pharmaceutics. He successfully obtained funding for key research projects, including a grant of 0.5 million PKR from the Higher Education Commission (HEC) of Pakistan for the fabrication, characterization, and in vitro evaluation of finasteride nanoparticles. Additionally, he received a substantial grant of 4.5 million PKR for his project on silica-based nanoparticles as hemostatic agents for controlling internal bleeding. Dr. Shah has also been recognized for his academic excellence, having supervised over 35 MPhil and five PhD students, and for his impactful research publications, which have contributed to advancements in drug delivery systems. His work has earned him respect and acknowledgment in the academic and research communities, reflecting his dedication to enhancing pharmaceutical sciences and improving patient care.

Conclusion

Dr. Kifayat Ullah Shah’s impressive academic credentials, extensive research experience, impactful publications, successful funding acquisitions, and contributions to education and administrative services strongly position him as a deserving candidate for the Research for Best Researcher Award. His ongoing commitment to advancing pharmaceutical sciences through research and mentorship further strengthens his suitability for this recognition.

Publication Top Notes

  • “Non-pharmacological management of hypertension: in the light of current research”
    • Journal: Irish Journal of Medical Science (1971-)
    • Cited by: 180
    • Year: 2019
    • Volume: 188
    • Pages: 437-452
  • “From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)”
    • Journal: Expert Opinion on Drug Delivery
    • Cited by: 148
    • Year: 2017
    • Volume: 14, Issue 11
    • Pages: 1325-1340
  • “Proniosomes derived niosomes: recent advancements in drug delivery and targeting”
    • Journal: Drug Delivery
    • Cited by: 121
    • Year: 2017
    • Volume: 24, Issue 2
    • Pages: 56-69
  • “A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers”
    • Journal: Carbohydrate Polymers
    • Cited by: 106
    • Year: 2020
    • Volume: 250
    • Pages: 116800
  • “Elemental analysis of some medicinal plants used in traditional medicine by atomic absorption spectrophotometer (AAS)”
    • Journal: Journal of Medicinal Plants Research
    • Cited by: 93
    • Year: 2010
    • Volume: 4, Issue 19
    • Pages: 1987-1990
  • “Polymeric nanogels as versatile nanoplatforms for biomedical applications”
    • Journal: Journal of Nanomaterials
    • Cited by: 81
    • Year: 2019
    • Volume: 2019, Issue 1
    • Pages: 1526186
  • “Hemostatic strategies for uncontrolled bleeding: A comprehensive update”
    • Journal: Journal of Biomedical Materials Research Part B: Applied Biomaterials
    • Cited by: 73
    • Year: 2021
    • Volume: 109
  • “Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product”
    • Journal: Journal of Drug Delivery Science and Technology
    • Cited by: 72
    • Year: 2019
    • Volume: 51
    • Pages: 583-590
  • “Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis”
    • Journal: International Journal of Clinical Pharmacy
    • Cited by: 56
    • Year: 2021
    • Volume: 43
    • Pages: 486-501
  • “Co-delivery strategies to overcome multidrug resistance in ovarian cancer”
    • Journal: International Journal of Pharmaceutics
    • Cited by: 47
    • Year: 2017
    • Volume: 533, Issue 1
    • Pages: 111-124
  • “Regulating drug release behavior and kinetics from matrix tablets based on fine particle‐sized ethyl cellulose ether derivatives: An in vitro and in vivo evaluation”
    • Journal: The Scientific World Journal
    • Cited by: 46
    • Year: 2012
    • Volume: 2012, Issue 1
    • Pages: 842348